Top Tech Companies (2,065)
Don't see your company?
Create a company profile
BioForce Nanosciences, Inc. develops and commercializes nanotech instruments, consumables, and applications for the life sciences.
Leading the field in the discovery of drugs that modulate the effects of cortisol. The adverse effects of excess cortisol have been Corcept’s focus since the company’s inception. Abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol.
Tansna Therapeutics is a developer of an oral anticonvulsant agent that reduces seizure frequency in patients with epilepsy.
Entact Bio is a preclinical stage biotechnology company developing a new class of drugs that enhance the function of beneficial proteins. Launched by a founding team deeply rooted in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, Entact has designed its proprietary Encompass™ platform to create enhancement-targeting chimeric (ENTAC™) medicines. ENTACs harness the ability of DUBs to regulate proteins. By leveraging this natural cellular mechanism to enhance protein function, Entact is expanding the universe of treatable diseases.
Faze Medicines is a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates. Our entire team is excited by the opportunity to harness this transformative moment in cell biology and translate discoveries in the lab to make a difference for patients. We are explorers in an emerging field, approaching this work with rigor and passion and having fun together along the way. We hope you’ll join us to write the next chapter of cell biology.
Circle Pharma initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP; we received additional seed funding from ShangPharma Investment Group Limited in November 2015. We recently raised Series B and Series C financing from The Column Group and NextTech Invest. We design and develop bioavailable macrocyclic peptide therapeutics against important clinical targets. We do this by applying a computational structure-based design approach that combines physics (conformational modeling), chemistry (innovative molecular components) and biology (protein target structure and function). We have selected intracellular protein-protein interactions that play key roles in cancer as the initial target group for our internal pipeline development. Circle is taking a new approach to the development of macrocylic peptide therapeutics that is based on the pioneering work of its founders to understand and computationally predict drug-like properties of macrocycles. Circle is advancing this understanding to design novel, inherently permeable macrocyclic peptide drug candidates against Circle’s internal targets and those of our collaboration partners. Our workflow includes the use of proprietary algorithms to design large, conformationally diverse, virtual libraries of cell permeable macrocyclic scaffolds that incorporate natural and non-natural backbone components. We deploy these virtual scaffold libraries in subsequent design steps that include the incorporation of functional side chains selected for both target binding and maintenance of permeability. Candidate compounds are synthesized and tested for both permeability and target affinity and the results are used to inform subsequent design cycles.
Agrinos, An American Vanguard Company, is a biological crop input provider committed to improving the productivity and sustainability of modern agriculture worldwide. Our products help farmers by providing increased crop yield and productivity, improved crop quality, enhanced efficiency of conventional fertilizer and a reduced environmental footprint. As world population grows rapidly and natural resources become increasingly strained, we need innovative, sustainable solutions that increase agricultural output, reduce inputs and ensure a safe, reliable food supply for all. As a worldwide leader in crop biologicals, Agrinos is proud to help meet that challenge. Agrinos products, developed through our proprietary High Yield Technology (HYT®) platform, have pioneered the quickly growing crop biologicals sector and have been proven to drive yield and quality improvements across diverse crops and environments across the globe. Agrinos’ global research, development and agronomy team is creating innovative products at the forefront of microbial and biological crop input innovation to improve the productivity and sustainability of today’s farmer. We deliver innovative products to improve the health of the soil microbiome—the critical foundation required for crops to reach their full potential—and ultimately bring prosperity to the grower. Groundbreaking innovation that enriches the soil microbiome is helping to shape the potential of modern agriculture—and Agrinos is a leader in delivering on that potential.
Morphogenesis is a clinical stage company developing novel cell and gene therapies
OncoSec Medical, a biotechnology company, develops treatments for advanced stage skin cancer patients.
Novir is a cutting-edge biotechnology company revolutionizing the way the world perceives and approaches healthcare. At Novir, we challenge the conventional care model by placing our focus on proactive measures rather than waiting for diagnoses. We firmly believe that care shouldn't start at diagnosis, but rather in the early stages of prevention. Our mission is to empower individuals to take charge of their health through innovative services and technologies that enable a pre-care pathway for anyone, anywhere, anytime.
Landmark Bio is a collective endeavor launched by leaders from academia, the life sciences industry, and world-renowned research hospitals to accelerate development and industrialization of next-generation genomic medicine. Inspired by recent advancements in cell and gene therapy, Landmark Bio was established to remove barriers in drug development, create accessible capability, expertise, and solutions, and offer a collaboration platform to advance manufacturing technologies for the new generation of medicines to come. Founding partners include Harvard University, Massachusetts Institute of Technology (MIT), Cytiva, FUJIFILM Diosynth Biotechnologies (FDB), and Alexandria Real Estate Equities, Inc. Other collaborating institutions include Beth Israel Deaconess Medical Center, Boston Children’s Hospital, Mass General Brigham, and the Dana-Farber Cancer Institute. For more information please contact [email protected]
Q-State Biosciences is a discovery technology and therapeutics company based in Cambridge, MA, that combines advanced human cellular models, unique measurement engineering and AI / machine learning into a proprietary platform that enables novel discovery of optimized genetically targeted medicines for epilepsy, pain, and other diseases of the CNS.
CARI Health is developing the next generation of Remote Medication Monitors that will allow clinicians to prescribe medications and receive real-time reporting on medication levels. CARI’s small, wireless sensors are worn on the patient’s skin and continuously monitor medication levels, sending alerts when necessary. With a CARI Remote Medication Monitor clinicians can provide precision care in this new era of telehealth medicine.
A Spokane, Wash.-based provider of molecular cytogenetic diagnostic services.
Selux Diagnostics is developing a Next Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. Earlier, better-informed treatment decisions will save lives, improve patient outcomes, decrease hospital lengths of stay and hospital acquired infections, and help combat the global antibiotic resistance epidemic. The CDC has cited bacterial resistance to antibiotics among the world’s deadliest and costliest health threats. Using current technologies, doctors must overprescribe powerful, broad-spectrum antibiotics for days while waiting for key diagnostic results to direct personalized therapy. SeLux NGP is the only platform capable of delivering personalized therapy results for all patients within a day of hospital entry, speeding this targeted treatment by an average of 2 days and as many as 4 days for patients infected with multi-drug resistant organisms. Selux Diagnostics was founded in 2014 by two Yale- and Harvard-trained engineers working in an improvised attic laboratory. On September 25, 2018, SeLux announced that it had signed a milestone-based contract worth up to $45 million with BARDA, a division of the U.S. Department of Health and Human Services’ (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR). SeLux immediately receives $9.3 million from BARDA to fund the clinical trial necessary for SeLux NGP, SeLux's next-generation phenotyping platform. The additional $36 million will fund the development of SeLux's second-generation rapid sepsis diagnostic system. SeLux has also raised $25 million in Series B financing to support the pivotal FDA trial for SeLux’s NGP platform. The round was led by Sands Capital Ventures and included returning investors RA Capital and Schooner Capital and new investors Sands Capital and Northpond Ventures.
We are designing RNA for next generation biomanufacturing and smart therapeutics. https://wayfinderbio.com
AIT Bioscience offers bioanalytical contract research services for preclinical and clinical trials.
Allele Biotechnology and Pharmaceuticals explores the mechanisms of biological processes to develop technologies and products.
SmartAnalyst is focused on supporting Bio-Pharma Innovation, with a mission to drive pipeline and portfolio value for global pharmaceutical and biotech companies. We provide Consulting services, Health Economic and Real World Evidence solutions, and Insights that are compelling, strategic and actionable. Founded in 2000 and a part of the UDG Healthcare group since 2018. Our three pillars of Strategy, Value and Insights are aimed at identifying and commercializing novel innovative therapies to improve patient outcomes and garner market success, providing compelling clinical and cost benefit evidence to secure advantageous reimbursement and access to patients, and data driven insights into future market dynamics to develop forward looking strategies for clinical differentiation and success. We have worked across all major therapeutic areas including oncology, immunology, neurosciences, cardiovascular and rare diseases. Oncology is the cornerstone of our consulting business.
WaveFront Dynamics is a medical device company with innovative wavefront diagnostic technology.
